Should I buy or sell Protalix BioTherapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PLX shares. View PLX analyst ratings or view top-rated stocks .

What is Protalix BioTherapeutics' stock price target for 2024?

1 brokers have issued twelve-month price objectives for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 769.6% from the stock's current price. View analysts price targets for PLX or view top-rated stocks among Wall Street analysts .

How have PLX shares performed in 2024?

Protalix BioTherapeutics' stock was trading at $1.78 on January 1st, 2024. Since then, PLX stock has decreased by 35.4% and is now trading at $1.15. View the best growth stocks for 2024 here .

When is Protalix BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PLX earnings forecast .

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSE:PLX) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04. The business had revenue of $10.49 million for the quarter, compared to analyst estimates of $8.15 million. Protalix BioTherapeutics had a trailing twelve-month return on equity of 29.73% and a net margin of 12.69%.

When did Protalix BioTherapeutics' stock split?

Shares of Protalix BioTherapeutics reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:PLX

Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PLX Stock Alerts

$1.15

+0.02 (+1.77%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.10
▼
$1.17
50-Day Range: $1.13
▼
$1.63
52-Week Range: $1.09
▼
$3.55

Volume: 449,784 shs
Average Volume: 332,392 shs
Market Capitalization: $84.01 million

P/E Ratio: 23.00
Dividend Yield: N/A
Price Target: $10.00

Get Protalix BioTherapeutics alerts:

Protalix BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 769.6% Upside
$10.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 478.57%
From $0.14 to $0.81 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.63 out of 5 stars

Medical Sector

439th out of 911 stocks

Biological Products, Except Diagnostic Industry

61st out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Protalix BioTherapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PLX.

0.0

Dividend Strength

Dividend Yield
Protalix BioTherapeutics does not currently pay a dividend.
Dividend Growth
Protalix BioTherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PLX.

1.1

News and Social Media Coverage

Search Interest
7 people have searched for PLX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.97% of the stock of Protalix BioTherapeutics is held by insiders.
Percentage Held by Institutions
Only 16.53% of the stock of Protalix BioTherapeutics is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Protalix BioTherapeutics are expected to grow by 478.57% in the coming year, from $0.14 to $0.81 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protalix BioTherapeutics is 23.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.60.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protalix BioTherapeutics is 23.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 256.72.
Price to Book Value per Share Ratio
Protalix BioTherapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Protalix BioTherapeutics Stock (NYSE:PLX)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Carmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PLX Stock News Headlines

March 16, 2024 | seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript

March 16, 2024 | uk.investing.com

Earnings call: Protalix BioTherapeutics reports fiscal year 2023 results

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 15, 2024 | ca.finance.yahoo.com

Production cuts, geopolitical tensions drive oil rally

March 15, 2024 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

PLX: Elfabrio Geographic Expansion

March 14, 2024 | finanznachrichten.de

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

March 14, 2024 | finance.yahoo.com

Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2024 | prnewswire.com

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

March 13, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Protalix BioTherapeutics's earnings report

March 13, 2024 | benzinga.com

Earnings Preview: Protalix BioTherapeutics

March 9, 2024 | edition.cnn.com

Protalix Biotherapeutics, Inc.

March 7, 2024 | finance.yahoo.com

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

February 23, 2024 | prnewswire.com

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

February 17, 2024 | ca.finance.yahoo.com

PLX Mar 2024 1.500 call

February 2, 2024 | msn.com

Abeona issues update on FDA market application for pz-cel

January 25, 2024 | entrepreneur.com

Will These 3 Biotech Stocks Make Gains in 2024?

December 26, 2023 | finance.yahoo.com

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

December 15, 2023 | benzinga.com

Protalix BioTherapeutics Stock (AMEX:PLX) Insider Trades

November 7, 2023 | finance.yahoo.com

PLX: More Regulatory Approvals

November 7, 2023 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript

November 6, 2023 | msn.com

American Well, Protalix BioTherapeutics among healthcare movers

November 6, 2023 | msn.com

Protalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $10.35M beats by $2.71M

November 6, 2023 | washingtonpost.com

Protalix: Q3 Earnings Snapshot

November 6, 2023 | markets.businessinsider.com

Protalix BioTherapeutics Inc. Q3 loss drops in line with estimates

November 6, 2023 | finance.yahoo.com

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

See More Headlines

Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:PLX
CUSIP: N/A
CIK: 1006281
Web: www.protalix.com
Phone: 201-696-9345
Fax: 972-4988-9489
Employees: 208
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +777.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.05
Trailing P/E Ratio: 22.80
Forward P/E Ratio: 8.14
P/E Growth: N/A
Net Income: $8.31 million
Net Margins: 12.69%
Pretax Margin: 13.08%
Return on Equity: 29.73%
Return on Assets: 10.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.54
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: $65.49 million
Price / Sales: 1.27
Cash Flow: $0.14 per share
Price / Cash Flow: 8.43
Book Value: $0.47 per share
Price / Book: 2.43

Miscellaneous

Outstanding Shares: 73,050,000
Free Float: 69,421,000
Market Cap: $83.28 million
Optionable: Optionable
Beta: 0.88

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Dror Bashan (Age 57)
President, CEO & Director
Comp: $473.16k
Mr. Eyal Rubin M.B.A. (Age 48)
Senior VP, CFO, Treasurer & Corporate Secretary
Comp: $813.73k
Mr. Yaron Naos (Age 60)
Senior Vice President of Operations
Comp: $409.95k
Ms. Yael Fellous
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protalix BioTherapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PLX shares.
View PLX analyst ratings or view top-rated stocks.
What is Protalix BioTherapeutics' stock price target for 2024?: 1 brokers have issued twelve-month price objectives for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 769.6% from the stock's current price.
View analysts price targets for PLX or view top-rated stocks among Wall Street analysts.
How have PLX shares performed in 2024?: Protalix BioTherapeutics' stock was trading at $1.78 on January 1st, 2024. Since then, PLX stock has decreased by 35.4% and is now trading at $1.15.
View the best growth stocks for 2024 here.
When is Protalix BioTherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PLX earnings forecast.

How were Protalix BioTherapeutics' earnings last quarter?: Protalix BioTherapeutics, Inc. (NYSE:PLX) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04. The business had revenue of $10.49 million for the quarter, compared to analyst estimates of $8.15 million. Protalix BioTherapeutics had a trailing twelve-month return on equity of 29.73% and a net margin of 12.69%.
When did Protalix BioTherapeutics' stock split?: Shares of Protalix BioTherapeutics reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
How do I buy shares of Protalix BioTherapeutics?: Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PLX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Protalix BioTherapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Protalix BioTherapeutics Stock (NYSE:PLX)

PLX Stock Price History

PLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™